EMA faces yet another transparency-related inquiry
This article was originally published in SRA
The EU Ombudsman has launched yet another investigation into the European Medicines Agency for not supporting the tenets of transparency and turning down a request from a member of the public - in this case a journalist from the New York Times - to have full access to two of its databases1,2.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.